CA 15-3 and bone scintigraphy in the follow-up of breast cancer

Autor: M. Seddiki, F. Montravers, V. Izrael, C. Philippe, J. N. Talbot, S. Uzan, N. Younsi
Rok vydání: 1998
Předmět:
0301 basic medicine
Adult
Cancer Research
medicine.medical_specialty
Clinical Biochemistry
CA 15-3
Pain
Bone Neoplasms
Breast Neoplasms
Scintigraphy
Sensitivity and Specificity
Bone and Bones
Pathology and Forensic Medicine
Metastasis
03 medical and health sciences
0302 clinical medicine
Breast cancer
Predictive Value of Tests
medicine
Biomarkers
Tumor

Humans
Radionuclide Imaging
Tumor marker
Aged
Neoplasm Staging
Retrospective Studies
Aged
80 and over

medicine.diagnostic_test
business.industry
Carcinoma
Mucin-1
Bone metastasis
Retrospective cohort study
Middle Aged
medicine.disease
Surgery
Carcinoembryonic Antigen
Neoplasm Proteins
030104 developmental biology
Oncology
Bone scintigraphy
Evaluation Studies as Topic
030220 oncology & carcinogenesis
Female
Radiology
business
Follow-Up Studies
Zdroj: The International journal of biological markers. 12(4)
ISSN: 0393-6155
Popis: By means of the retrospective study of the clinical records of 158 women followed for breast cancer, we aimed to evaluate the consequences of a non-systematic indication for bone scan (BS) based either on CA 15-3 levels alone or a combination of tumor marker levels and clinical criteria. With the first option, the negative predictive value was 95% and 82% of the BS would have been avoided. With the second option, the negative predictive value was 97% and 59% of the BS would have been avoided. Furthermore, the preliminary results of a longitudinal study showed that those patients with normal CA 15-3 levels and positive bone scans showed a subsequent rise in CA 15-3 levels which frequently became elevated with an average delay of 15 months. Omission of systematic bone scans in the follow-up of breast cancer patients is likely to lead to a delay in the diagnosis of bone metastasis in 3% to 5%, the consequences of which have to be examined carefully.
Databáze: OpenAIRE